Date de publication : 21 mars 2025
Team 3 from INCIT Lab Inserm U1302 (Nantes) is part of the Inserm Impact Santé project DARVAC « Development of vaccines offering innovative early protection against non-viral cancers » based on ghost (Dark) proteins. The project is led by Jerome Galon, with Michel Salzet (Prism – Lille), Jean-Bastiste Latouche (Rouen), Olivier Adotevi (RIGHT – Besançon) and our Team (team 3, INCIT- François Lang, Catherine Rabu and Nathalie Labarriere) as co-investigators.